Clinical Trials · NCT02488512

Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas

TerminatedPhase 2Octreotide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Enrollment
1
Start date
Dec 2016
Locations
1 site, Italy
Primary endpoint
overall response rate (ORR)
View Octreotide compound reference